[go: up one dir, main page]

MXPA02011844A - Compuestos con un grupo de sulfonamida, y composiciones farmaceuticas que contienen estos compuestos. - Google Patents

Compuestos con un grupo de sulfonamida, y composiciones farmaceuticas que contienen estos compuestos.

Info

Publication number
MXPA02011844A
MXPA02011844A MXPA02011844A MXPA02011844A MXPA02011844A MX PA02011844 A MXPA02011844 A MX PA02011844A MX PA02011844 A MXPA02011844 A MX PA02011844A MX PA02011844 A MXPA02011844 A MX PA02011844A MX PA02011844 A MXPA02011844 A MX PA02011844A
Authority
MX
Mexico
Prior art keywords
compounds
group
erythrocytes
substances
pharmaceutical compositions
Prior art date
Application number
MXPA02011844A
Other languages
English (en)
Inventor
Sigfrid Schwarz
Original Assignee
Jenapharm Gmbh Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7644802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02011844(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jenapharm Gmbh Co Kg filed Critical Jenapharm Gmbh Co Kg
Publication of MXPA02011844A publication Critical patent/MXPA02011844A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invencion se refiere a compuestos que actuando como prodrogas y/o soportes hacen posible la incorporacion de un ingrediente activo en los eritrocitos y/o el enlace de un ingrediente activo a los eritrocitos, siendo que la incorporacion de los compuestos en y/o el enlace de los compuestos a los eritrocitos es hecho posible por el grupo -SO2NR1R2, siendo que R1 y R2, independientes uno de otro significan un atomo de hidrogeno, un grupo acilo, un grupo alquilo, un grupo cicloalquilo, un grupo arilo, un grupo ciano o un grupo hidroxi. Mediante la prodroga de conformidad con la invencion se obtiene la disponibilidad oral en un grado razonable o la mejora decisiva con respecto a la actividad oral de los ingredientes activos, como sustancias endogenas, sustancias naturales y sustancias sinteticas con valiosas propiedades terapeuticas con un marcado efecto de "primer paso".
MXPA02011844A 2000-05-31 2001-05-08 Compuestos con un grupo de sulfonamida, y composiciones farmaceuticas que contienen estos compuestos. MXPA02011844A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10027887A DE10027887A1 (de) 2000-05-31 2000-05-31 Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
PCT/EP2001/005169 WO2001091797A2 (de) 2000-05-31 2001-05-08 Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Publications (1)

Publication Number Publication Date
MXPA02011844A true MXPA02011844A (es) 2004-05-17

Family

ID=7644802

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011844A MXPA02011844A (es) 2000-05-31 2001-05-08 Compuestos con un grupo de sulfonamida, y composiciones farmaceuticas que contienen estos compuestos.

Country Status (29)

Country Link
US (2) US7507725B2 (es)
EP (1) EP1294402B2 (es)
JP (1) JP2003534386A (es)
KR (3) KR20080038460A (es)
CN (1) CN1441678A (es)
AT (1) ATE315407T1 (es)
AU (2) AU6593301A (es)
BG (1) BG107556A (es)
BR (1) BR0111294A (es)
CA (1) CA2410630A1 (es)
CZ (1) CZ2003621A3 (es)
DE (2) DE10027887A1 (es)
DK (1) DK1294402T4 (es)
EA (1) EA006432B1 (es)
ES (1) ES2256256T5 (es)
HR (1) HRP20021038B1 (es)
HU (1) HUP0301949A3 (es)
IL (2) IL152932A0 (es)
ME (1) MEP14608A (es)
MX (1) MXPA02011844A (es)
NO (1) NO20025739L (es)
NZ (1) NZ535201A (es)
PL (1) PL206462B1 (es)
PT (1) PT1294402E (es)
SK (1) SK2912003A3 (es)
UA (1) UA76953C2 (es)
WO (1) WO2001091797A2 (es)
YU (1) YU90102A (es)
ZA (1) ZA200209490B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US8026229B2 (en) 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates
DE102004025985A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
DE102004025986A1 (de) * 2004-05-21 2005-12-15 Schering Ag Steroid-Prodrugs mit androgener Wirkung
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
US20050282793A1 (en) * 2004-05-21 2005-12-22 Ralf Wyrwa Steroid prodrugs with androgenic action
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
DE102005057224A1 (de) 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005057225A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
DE102005057421A1 (de) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag Heteroaromatische Sulfonamid-Prodrugs
DE102005057408A1 (de) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag Sulfamoylsulfonat-Prodrugs
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
US8777182B2 (en) 2008-05-20 2014-07-15 Grinon Industries Fluid transfer assembly and methods of fluid transfer
WO2009143164A1 (en) 2008-05-20 2009-11-26 Grinon Industries Fluid transfer assembly and methods of fluid transfer
US9100458B2 (en) * 2008-09-11 2015-08-04 At&T Intellectual Property I, L.P. Apparatus and method for delivering media content
CN101987104A (zh) * 2009-08-05 2011-03-23 天津金耀集团有限公司 一种杂芳香基氨磺酰基羧酸酯碳酸酐酶抑制剂的眼用组合物
CN101987102A (zh) * 2009-08-05 2011-03-23 天津金耀集团有限公司 一种糖皮质激素杂芳香基氨磺酰基羧酸酯的眼用抗炎组合物
MX363934B (es) 2011-12-30 2019-04-08 Grinon Ind Ensamble de transferencia de fluido y metodos de transferencia de fluido.
CN105636592A (zh) * 2013-07-11 2016-06-01 伊万斯彻有限公司 形成前药的化合物
EP3173113A1 (en) 2015-11-27 2017-05-31 Sanofi-Aventis Deutschland GmbH An injection needle assembly
US11571505B2 (en) 2015-11-27 2023-02-07 Sanofi-Aventis Deutschland Gmbh Drug delivery device with a cap
MX2020003470A (es) 2017-10-19 2020-10-01 Evestra Inc Anticonceptivos de profarmacos de progestina de accion mas prolongada.
JP2023552699A (ja) * 2020-11-17 2023-12-19 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1203042B (de) * 1963-11-21 1965-10-14 Schering Ag Fungizide Mittel
GB1593609A (en) 1978-01-31 1981-07-22 Christiaens Sa A Pyridine sulfonamides
US4244940A (en) * 1978-09-05 1981-01-13 Bio-Rad Laboratories, Inc. Single-incubation two-site immunoassay
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5001234A (en) † 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4792569A (en) 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
US5116828A (en) 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5025031A (en) * 1989-11-30 1991-06-18 A. H. Robins Co., Inc. Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
GB9118478D0 (en) * 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
DE4447715C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US5571933A (en) 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
US5705495A (en) * 1995-10-19 1998-01-06 Jenapharm Gmbh & Co. Kg. Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for their production and pharmaceuticals containing these compounds
DE19540233B4 (de) * 1995-10-19 2005-08-25 Schering Ag Sulfamat-Derivate von 1,3,5(10)-Estratrien-Derivaten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19712488A1 (de) † 1997-03-25 1998-10-01 Knoell Hans Forschung Ev Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben
DE19723794A1 (de) * 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
AU5027599A (en) 1998-07-29 2000-02-21 Crisplant A/S Parcel singulation system
US6583130B1 (en) 1999-09-13 2003-06-24 Schering Ag C13-substituted estra-1,3,5,(10)-trien-3-yl sulfamates, methods of preparing same, and pharmaceutical compositions containing these compounds
US6958327B1 (en) * 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
KR20020087930A (ko) * 2000-01-14 2002-11-23 스테릭스 리미티드 조성물
EP1272504B1 (de) 2000-04-12 2007-05-30 Bayer Schering Pharma Aktiengesellschaft 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
CA2438272A1 (en) 2001-03-02 2002-10-10 John Macor Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US20020156068A1 (en) * 2001-03-22 2002-10-24 Behan Dominic P. Anti-psychosis combination
US6956031B2 (en) 2002-03-27 2005-10-18 Schering Aktiengesellschaft 11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring
US7414043B2 (en) 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
DE10226326A1 (de) 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene
PL1689410T3 (pl) 2003-11-26 2008-10-31 Bayer Schering Pharma Ag Sposób zapobiegania i leczenia nadciśnieniowych chorób serca za pomocą selektywnych estrogenów: 8ß-winylo-estra-1,3,5(10)-trien-3,17ß-diolu i 17ß-fluoro-9a-winylo-estra-1,3,5(10)-trien-3,16a-diolu
DE102004025985A1 (de) 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
DE102004025966A1 (de) 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102004025986A1 (de) 2004-05-21 2005-12-15 Schering Ag Steroid-Prodrugs mit androgener Wirkung
US20050277625A1 (en) 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450

Also Published As

Publication number Publication date
DE50108674D1 (de) 2006-04-06
PL361426A1 (pl) 2004-10-04
IL152932A (en) 2007-07-04
DK1294402T3 (da) 2006-05-22
US20090023896A1 (en) 2009-01-22
UA76953C2 (en) 2006-10-16
IL152932A0 (en) 2003-06-24
PT1294402E (pt) 2006-05-31
CN1441678A (zh) 2003-09-10
WO2001091797A3 (de) 2002-06-20
AU2001265933B2 (en) 2007-10-18
MEP14608A (bs) 2010-06-10
DK1294402T4 (da) 2009-11-23
ZA200209490B (en) 2005-03-10
BR0111294A (pt) 2003-06-10
KR20090090398A (ko) 2009-08-25
NO20025739D0 (no) 2002-11-29
EP1294402A2 (de) 2003-03-26
EA006432B1 (ru) 2005-12-29
WO2001091797A2 (de) 2001-12-06
JP2003534386A (ja) 2003-11-18
HUP0301949A2 (hu) 2003-09-29
EP1294402B1 (de) 2006-01-11
ES2256256T5 (es) 2009-12-11
YU90102A (sh) 2006-05-25
PL206462B1 (pl) 2010-08-31
ES2256256T3 (es) 2006-07-16
EA200201201A1 (ru) 2003-06-26
DE10027887A1 (de) 2001-12-13
SK2912003A3 (en) 2003-09-11
US7507725B2 (en) 2009-03-24
HRP20021038A2 (en) 2004-10-31
US20040014781A1 (en) 2004-01-22
KR20080038460A (ko) 2008-05-06
HRP20021038B1 (hr) 2008-08-31
EP1294402B2 (de) 2009-08-12
NZ535201A (en) 2007-01-26
AU6593301A (en) 2001-12-11
NO20025739L (no) 2002-11-29
ATE315407T1 (de) 2006-02-15
KR20030017524A (ko) 2003-03-03
CZ2003621A3 (cs) 2003-12-17
HUP0301949A3 (en) 2010-01-28
CA2410630A1 (en) 2002-11-28
BG107556A (bg) 2004-01-30

Similar Documents

Publication Publication Date Title
MXPA02011844A (es) Compuestos con un grupo de sulfonamida, y composiciones farmaceuticas que contienen estos compuestos.
CR5908A (es) Composiciones cosmeticas con dbs y siliconas funcionalizadas
ES2171533T3 (es) Composiciones que contienen nebivolol micronizado.
GT200400126A (es) Compuestos activos antitranspirantes de aluminio/zirconio/glicina, estabilizados con betaina
SV1999000251A (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina ref. pcl0085/82805/bb
AR047277A1 (es) Mezclas insecticidas sinergicas
SV1999000118A (es) Nuevos derivados de pirazol substituidos ref. lea 33188-sv
ES2188013T3 (es) Composicion biocida sinergica.
MXPA05001061A (es) Composiciones farmaceuticas, acuosas de 2,6-diisopropilfenol.
BR0009893A (pt) Composição de cuidado com a pele; e uso de uma composição de cuidado com a pele
AR012764A1 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, usos y procedimientos para prepararlos.
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
AR024810A1 (es) Composiciones cosmeticas
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
BR0111678A (pt) Composições medicinais contendo derivados de propenona
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
TR200003156T2 (tr) Bir aktif içerik olarak izomalt içeren terapötik soğuk algınlığına karşı ajan.
CO5021199A1 (es) Derivados de 8-fenilxantina
ES2193297T3 (es) Agentes que previenen el mal olor humano.
BRPI0410504A (pt) composição cosmética sólida, processo de preparação de bastão desodorante ou antitranspirante e método cosmético de inibição ou controle da transpiração e/ou geração de mau odor
TR200002266T2 (tr) İnterlokin-6 üretimini canlandırıcı etkinliğe sahip bir bileşik içeren kozmetik kompozisyon.
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
BRPI0508232A (pt) sìntese de epotilonas, intermediários das mesmas, análogos e usos das mesmas
BR9911639A (pt) Composições capilares não enxaguáveis contendo um diol
ES2193106T3 (es) Nuevas chalconas.

Legal Events

Date Code Title Description
FG Grant or registration